Schaefer, Inga-Marie http://orcid.org/0000-0001-9710-5500
Hemming, Matthew L. http://orcid.org/0000-0003-4674-7778
Lundberg, Meijun Z.
Serrata, Matthew P.
Goldaracena, Isabel
Liu, Ninning
Yin, Peng
Paulo, Joao A. http://orcid.org/0000-0002-4291-413X
Gygi, Steven P.
George, Suzanne
Morgan, Jeffrey A.
Bertagnolli, Monica M.
Sicinska, Ewa T.
Chu, Chen
Zheng, Shanshan
Mariño-Enríquez, Adrian http://orcid.org/0000-0002-7680-9901
Hornick, Jason L. http://orcid.org/0000-0001-6475-8345
Raut, Chandrajit P.
Ou, Wen-Bin http://orcid.org/0000-0002-6311-9442
Demetri, George D.
Saka, Sinem K. http://orcid.org/0000-0002-5017-379X
Fletcher, Jonathan A.
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (K08CA241085, UH3CA25513303, UH3CA25513303, 1DP1GM133052, UH3CA25513303, 1DP1GM133052, UH3CA25513303, 1DP1GM133052)
SARC (Sarcoma Alliance for Research through Collaboration) Young Investigator Award
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
United States Department of Defense | United States Navy | Office of Naval Research (N00014-18-1-2549)
Wyss Institute Validation Project Program
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01GM132129)
Pfizer and Lilly through the Alliance for Clinical Trials in Oncology
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
European Molecular Biology Laboratory (EMBL) core funding
Article History
Received: 22 April 2022
Revised: 7 September 2022
Accepted: 12 September 2022
First Online: 29 September 2022
Competing interests
: SKS and PY are inventors for a US patent application for the multiplexed imaging technology used in this work. PY is a co-founder of Ultivue, Inc. and NuProbe Global. SG serves as consultant/advisory board member to Deciphera Pharmaceuticals, Blueprint Medicines, Daiichi-Sankyo, Kayothera, Immunicum, Eli Lilly, Bayer, Ayala; reports research funding to the institution by Deciphera Pharmaceuticals, Blueprint Medicines, Daiichi-Sankyo, Theseus Pharmaceuticals, Merck, Eisai, Springworks, Pfizer and Bayer; holds equity at Abbott Laboratories; and receives royalties from Wolters Kluwer/UpToDate. MMB serves on the Board of Directors of Natera, Inc., and Leap Therapeutics. JLH serves as a consultant to Aadi Biosciences and TRACON Pharmaceuticals. GDD serves as a Board of Directors member with minor equity holding in Blueprint Medicines; serves as co-founder with minor equity holding in IDRX; serves as consultant/SAB member with minor equity holding in G1 Therapeutics, Caris Life Sciences, Erasca Pharmaceuticals, RELAY Therapeutics, Bessor Pharmaceuticals, CellCarta, IKENA Oncology, Kojin Therapeutics, Acrivon Therapeutics; serves as a scientific consultant with sponsored research to Dana-Farber to Bayer, Pfizer, Novartis, Roche/Genentech, Janssen, PharmaMar, Daiichi-Sankyo, AdaptImmune; serves as a scientific consultant to GlaxoSmithKline, EMD-Serono, MEDSCAPE, Mirati, WCG/Arsenal Capital, RAIN Therapeutics; and receives Novartis royalty to Dana-Farber for use patent of imatinib in GIST. The remaining authors declare no competing interests.
: Patient sample collection and analysis were conducted following protocols approved by the Dana-Farber/Brigham and Women’s Hospital Institutional Review Board. Written informed consent was obtained from patients for use of samples. The study was performed in accordance with the Declaration of Helsinki.
: Not applicable.